Cardiovascular Research · 2024 · 32 citations · 90 references
PharmacyPharmaceuticsPharmacologyMolecular ImagingNanomaterialsTheranosticsInorganic NanoparticlesLipid-based NanoparticlesNanocarriers For TherapeuticsNanomedicineNanoparticle DesignTheranostic NanoparticlesCholesterol EffluxMultifunctional NanoparticlesMultifunctional NanoplatformsNanoparticle Imaging AgentsNanoparticle-based Macrophage TargetingNanoparticle-mediated ImagingNanoparticlesTheranostic Agents
Despite the emergence of novel diagnostic, pharmacological, interventional, and prevention strategies, atherosclerotic cardiovascular disease remains a significant cause of morbidity and mortality. Nanoparticle (NP)-based platforms encompass diverse imaging, delivery, and pharmacological properties that provide novel opportunities for refining diagnostic and therapeutic interventions for atherosclerosis at the cellular and molecular levels. Macrophages play a critical role in atherosclerosis and therefore represent an important disease-related diagnostic and therapeutic target, especially given their inherent ability for passive and active NP uptake. In this review, we discuss an array of inorganic, carbon-based, and lipid-based NPs that provide magnetic, radiographic, and fluorescent imaging capabilities for a range of highly promising research and clinical applications in atherosclerosis. We discuss the design of NPs that target a range of macrophage-related functions such as lipoprotein oxidation, cholesterol efflux, vascular inflammation, and defective efferocytosis. We also provide examples of NP systems that were developed for other pathologies such as cancer and highlight their potential for repurposing in cardiovascular disease. Finally, we discuss the current state of play and the future of theranostic NPs. Whilst this is not without its challenges, the array of multifunctional capabilities that are possible in NP design ensures they will be part of the next frontier of exciting new therapies that simultaneously improve the accuracy of plaque diagnosis and more effectively reduce atherosclerosis with limited side effects.
90
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker, Tom Thurén, Jean MacFadyen et al. · New England Journal of Medicine · 2017 · 9.1K citations · Full text
Nanometre-scale thermometry in a living cell
Georg Kucsko, Peter C. Maurer, Norman Y. Yao et al. · Nature · 2013 · 2K citations · Full text
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray, R. Scott Wright, David Kallend et al. · New England Journal of Medicine · 2020 · 1.6K citations · Full text
Nanoparticle uptake: The phagocyte problem
Heather H. Gustafson, Dolly Holt‐Casper, David W. Grainger et al. · Nano Today · 2015 · 1.4K citations · Full text